J&J Completes Tipifarnib Submission For Leukemia Under Pilot 1 Program
This article was originally published in The Pink Sheet Daily
Executive Summary
The oral oncologic, known by the proposed trade name Zarnestra, could be approved by the end of the first half based on J&J's filing under the continuous marketing application pilot program and an expected six-month review. Submission is premised on Phase II response data.